Gaviscon (alginates)
Pronunciation: GAV-iss-kon.
- Generic name
- alginic acid / sodium alginate (with potassium or sodium bicarbonate, or aluminium hydroxide/magnesium carbonate depending on market formulation)
- Drug class
- Alginate-based antacid / raft-forming reflux suppressant
- Form
- Liquid suspension or chewable tablet
- Route
- Oral
- Legal status
- Over-the-counter (non-prescription / general sale)
Availability and supply rules vary by country
Trade names by country: United States · United Kingdom · Canada · Australia · New Zealand
Australia: Gaviscon Dual Action / Extra Strength (5) · Full directory
What alginic acid / sodium alginate (with potassium or sodium bicarbonate, or aluminium hydroxide/magnesium carbonate depending on market formulation) is and how it works
Gaviscon is an over-the-counter medicine for heartburn and acid reflux (gastro-oesophageal reflux). Alginate-based versions work by forming a floating gel 'raft' on top of the stomach contents that physically blocks acid from splashing back into the food pipe (oesophagus); other formulations work as a more traditional antacid that neutralises stomach acid. (2) (1)
Gaviscon is intended for short-term, as-needed relief of heartburn and indigestion. If your symptoms do not improve within about a week, or keep coming back, see a doctor or pharmacist rather than continuing to self-treat.
Mechanism of action: how alginic acid / sodium alginate (with potassium or sodium bicarbonate, or aluminium hydroxide/magnesium carbonate depending on market formulation) works
Alginate-based formulations react with stomach acid to form a low-density, near-neutral-pH gel 'raft' that floats above the gastric contents and is preferentially refluxed instead of acid, providing a physical and chemical barrier effect lasting up to about 4 hours. Aluminium/magnesium-based formulations act as classic antacids, neutralising gastric acid directly. (2) (1)
What alginic acid / sodium alginate (with potassium or sodium bicarbonate, or aluminium hydroxide/magnesium carbonate depending on market formulation) is used for
Heartburn and acid indigestion
Relieves heartburn, acid indigestion, sour stomach, and upset stomach associated with these symptoms. (1)
Acid reflux (GORD/GERD) symptoms, including in pregnancy
Alginate-forward 'Advance'-type formulations treat symptoms of acid reflux such as regurgitation, heartburn, and reflux-related indigestion, including reflux symptoms during pregnancy and symptoms of reflux affecting the throat (laryngopharyngeal reflux). (2) (3)
Before taking alginic acid / sodium alginate (with potassium or sodium bicarbonate, or aluminium hydroxide/magnesium carbonate depending on market formulation)
Do not take / not appropriate for
- Do not take Gaviscon if you have had an allergic reaction to it or to any of its ingredients. (all countries) (2)
Tell your clinician about
- Whether you are on a low-sodium or low-potassium diet, or have heart failure or kidney problems, since some Gaviscon formulations contain meaningful amounts of sodium and/or potassium.
- All other medicines you take, especially antibiotics (tetracyclines, fluoroquinolones), iron supplements, or thyroid hormone, since Gaviscon can reduce how well these are absorbed if taken too close together.
- Pregnancy or breastfeeding, so the most appropriate formulation and dose can be confirmed for you.
- Whether your symptoms have lasted more than a week, are severe, or are accompanied by warning signs such as unexplained weight loss, difficulty swallowing, or vomiting blood -- these need medical assessment rather than ongoing self-treatment.
How to take alginic acid / sodium alginate (with potassium or sodium bicarbonate, or aluminium hydroxide/magnesium carbonate depending on market formulation)
- Check the specific product's label for its exact active ingredients and dose, since Gaviscon formulations vary by country and by product line (e.g. 'Advance', 'Extra Strength', 'Dual Action').
- Leave a gap of about 2 hours between taking Gaviscon and taking other oral medicines, particularly antibiotics, iron tablets, or thyroid hormone, since Gaviscon can reduce their absorption if taken at the same time.
- Alginate 'Advance'-type formulations are usually taken after meals and at bedtime, since this is when reflux is most likely.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6)
Missed dose
Gaviscon is usually taken as needed for symptoms rather than on a fixed schedule, so a 'missed dose' does not generally apply -- simply take the next dose when you next have symptoms, without exceeding the maximum daily amount on the label.
Overdose
Taking much more than the labelled maximum daily dose is unlikely to cause serious harm for most people, but can cause stomach upset, and in people with kidney problems or on a low-sodium/potassium diet could contribute to a higher intake of these minerals than intended. If a large amount has been swallowed, especially by a child, or if you feel unwell, contact a doctor, pharmacist, or poison control for advice. (2)
Side effects
Side effects and their urgency vary; report severe, persistent, or concerning symptoms.
Gaviscon is generally very well tolerated when used as directed; side effects are uncommon.
What to notice: Gaviscon is generally very well tolerated when used as directed; side effects are uncommon.
What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2)
Occasional bloating or a feeling of fullness has been reported with alginate raft-forming formulations.
What to notice: Occasional bloating or a feeling of fullness has been reported with alginate raft-forming formulations.
What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2)
Aluminium/magnesium-containing formulations (such as the US product) can occasionally cause constipation (aluminium) or a laxative effect (magnesium).
What to notice: Aluminium/magnesium-containing formulations (such as the US product) can occasionally cause constipation (aluminium) or a laxative effect (magnesium).
What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)
Serious warnings
Signs of a serious allergic reaction — emergency
Symptoms: Swelling of the face, lips, tongue, or throat; difficulty breathing; widespread rash or hives.
Action: Seek emergency medical help immediately. (2)
Symptoms that do not fit ordinary heartburn (e.g. difficulty or pain swallowing, unexplained weight loss, vomiting blood, or black/tarry stools) — high caution
Symptoms: Persistent difficulty swallowing, unintentional weight loss, vomiting blood or material that looks like coffee grounds, or black, tarry stools.
Action: These are not managed with an over-the-counter antacid alone -- see a doctor promptly for assessment. (2)
Interactions
- Leave about a 2-hour gap between Gaviscon and other oral medicines, especially tetracycline or fluoroquinolone antibiotics, iron supplements, and thyroid hormone tablets, since taking them together can reduce how much of those medicines your body absorbs. (2)
- Aluminium/magnesium-containing formulations (such as the US product) can also reduce the absorption of some other medicines when taken at the same time -- the same 2-hour spacing principle applies generally to antacids. (1)
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
Alginate 'Advance'-type Gaviscon formulations are considered safe to use during pregnancy for reflux symptoms, based on available studies showing no malformation or foetal/neonatal toxicity signal. Check the label of your specific product, and ask a pharmacist or midwife if unsure. (1) (2) (3) (4) (5) (6)
Breastfeeding
No known effect on breastfed infants has been identified for alginate-based Gaviscon formulations. (1) (2) (3) (4) (5) (6)
Children
Not recommended in children under 12 except on specific medical advice. (1) (2) (3) (4) (5) (6)
Elderly
No specific age-related dose adjustment is described; older adults with kidney impairment or heart failure should pay particular attention to the sodium/potassium content of the formulation chosen. (1) (2) (3) (4) (5) (6)
Hepatic_impairment
No specific liver-related restriction identified in the sources reviewed. (1) (2) (3) (4) (5) (6)
Renal_impairment
People with reduced kidney function should be cautious with the sodium and potassium content of alginate 'Advance'-type formulations, and with the aluminium/magnesium content of antacid-type formulations (such as the US product) -- ask a pharmacist which formulation and dose is appropriate. (1) (2) (3) (4) (5) (6)
Source_ids
UK-EMC-GAVISCON-ADVANCE-2026,US-DAILYMED-GAVISCON-2026 (1) (2) (3) (4) (5) (6)
Monitoring
Before starting
- Confirm the symptoms are ordinary heartburn/reflux and not a warning sign needing medical assessment (see serious warnings).
During treatment
- Review with a doctor or pharmacist if symptoms have not improved within about 7 days.
- Do not use the maximum labelled dose for more than 2 weeks without medical supervision.
- Watch for new or worsening symptoms such as difficulty swallowing or weight loss, which need medical review.
Storage
Store at room temperature, away from heat and moisture, as directed on the product label. Keep out of reach of children.
Professional information
Clinician-facing context only, sourced from the current US OTC Drug Facts label and UK/Ireland SmPCs; verify against the current local label before recommending, since formulation varies significantly by market.
United Kingdom / Ireland (European Union)
Indication: Symptoms of gastro-oesophageal reflux (heartburn, regurgitation, reflux-related indigestion)
Dose summary: Adults/adolescents 12+: 5-10 mL suspension or 1-2 chewable tablets after meals and at bedtime. Children under 12: medical advice only.
Renal context: Caution with sodium/potassium load in significant renal impairment; no formal dose adjustment specified. (2) (3)
United States
Indication: Heartburn, acid indigestion, sour/upset stomach (OTC antacid monograph)
Dose summary: Regular Strength: 1-2 tablespoonfuls up to 4x/day (max 8 tbsp/24h). Extra Strength: 2-4 teaspoonfuls up to 4x/day (max 16 tsp/24h). Max dose not to exceed 2 weeks without medical supervision.
Renal context: Aluminium/magnesium content warrants caution in significant renal impairment; consult a pharmacist or doctor. (1)
Hepatic guidance
No specific hepatic dosing guidance identified in the sources reviewed.
Overdose note
Low acute toxicity; excess use mainly risks gastrointestinal upset (constipation with aluminium, loose stools with magnesium) or excess sodium/potassium intake in susceptible patients. (2) (1)
Frequently asked questions
Is Gaviscon the same product in every country?
No. The core brand is sold worldwide, but the exact active ingredients differ: most markets (UK, Ireland/EU, Canada, Australia, New Zealand) mainly sell alginate + potassium or sodium bicarbonate 'raft-forming' formulations such as Gaviscon Advance, while the current US OTC Gaviscon is an aluminium hydroxide/magnesium carbonate antacid that also contains sodium alginate. Always check your specific product's label. (1) (2)
Can I take Gaviscon with my other medicines?
Leave about a 2-hour gap between Gaviscon and other oral medicines, particularly certain antibiotics, iron supplements, and thyroid hormone, since taking them close together can reduce how well your body absorbs those medicines. (2)
Is Gaviscon safe during pregnancy?
Alginate-based 'Advance'-type Gaviscon formulations are commonly used and considered safe for reflux symptoms in pregnancy, but check with your pharmacist or midwife about the specific product and formulation available to you. (2)
What is the mechanism of action of alginic acid / sodium alginate (with potassium or sodium bicarbonate, or aluminium hydroxide/magnesium carbonate depending on market formulation)?
Alginate-based formulations react with stomach acid to form a low-density, near-neutral-pH gel 'raft' that floats above the gastric contents and is preferentially refluxed instead of acid, providing a physical and chemical barrier effect lasting up to about 4 hours. Aluminium/magnesium-based formulations act as classic antacids, neutralising gastric acid directly. (2) (1)
References
- GAVISCON (aluminum hydroxide and magnesium carbonate) liquid antacid -- Drug Facts labelU.S. Food and Drug Administration / DailyMed (NIH), OTC Drug Facts label · United States · accessed 2026-07-29 · source 1
- Gaviscon Advance Peppermint Flavour Oral Suspension -- Summary of Product Characteristicselectronic medicines compendium (emc), United Kingdom -- Reckitt Benckiser Healthcare (UK) Ltd · United Kingdom · accessed 2026-07-29 · source 2
- Gaviscon Advance Chewable Tablets (sodium alginate 500 mg, potassium hydrogen carbonate 100 mg) -- Summary of Product Characteristics / LicenceHealth Products Regulatory Authority (HPRA), Ireland -- an EU member state competent authority · European Union · accessed 2026-07-29 · source 3
- GAVISCON LIQUID - Fruit & Mint Flavours (DIN 02142643) -- historical DPD listing; current Gaviscon Regular/Extra Strength products remain marketed in Canada under the Gaviscon brand (Haleon/GSK Consumer Healthcare)Health Canada Drug Product Database (DPD) · Canada · accessed 2026-07-29 · source 4
- GAVISCON DUAL ACTION mixed berry flavour oral liquid -- ARTG entryTherapeutic Goods Administration (TGA), Australia · Australia · accessed 2026-07-29 · source 5
- Gaviscon Original / Dual Action / Extra Strength -- New Zealand retail availabilityNew Zealand general-sale medicine market confirmation (Chemist Warehouse NZ, Unichem NZ pharmacy retail listings) · New Zealand · accessed 2026-07-29 · source 6
Brand names by country
Single-ingredient alginic acid / sodium alginate (with potassium or sodium bicarbonate, or aluminium hydroxide/magnesium carbonate depending on market formulation) names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- Gaviscon (Regular Strength / Extra Strength) (1)FDA OTC monograph confirmed · aluminum hydroxide 95 mg + magnesium carbonate 358 mg per 15 mL (Regular); aluminum hydroxide 254 mg + magnesium carbonate 237.5 mg per 5 mL (Extra Strength) · Reckitt Benckiser / Haleon (current US marketer)
United Kingdom
- Gaviscon Advance (2)MHRA licensed emc smpc confirmed GSL · sodium alginate 1000 mg + potassium hydrogen carbonate 200 mg per 10 mL · Reckitt Benckiser Healthcare (UK) Ltd
Canada
- Gaviscon (Regular Strength / Extra Strength / Advance) (4)Health Canada DIN historical plus current retail confirmed · varies by product; historical DIN 02142643: aluminum hydroxide 100 mg + sodium alginate 250 mg per 5 mL · Haleon / GSK Consumer Healthcare (current Canadian marketer)
Australia
- Gaviscon Dual Action / Extra Strength (5)TGA ARTG registered confirmed unscheduled · varies by product; e.g. calcium carbonate + sodium alginate + sodium bicarbonate · Reckitt Benckiser Pty Ltd
New Zealand
- Gaviscon Original / Dual Action / Extra Strength (6)confirmed general sale no medsafe data sheet required · not specified in fetched source · not specified in fetched source
View brands in additional countries.
European Union
Gaviscon Advance (3)